Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the Multiple Sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category. The increased risk tolerance and the expanding number of therapies in multiple sclerosis is evolving the treatment strategies for all forms of MS.
The research plan is designed to address key questions such as: Which DMTs will feel the greatest impact of Ocrelizumab’s launch? How are the three Oral Agents delivering on the key attributes neurologists look for? What are neurologists’ attitudes towards Lemtrada? What is the impact of patient education on treatment compliance and patient knowledge and specific treatment requests on prescribing? How are PML concerns affecting Tecfidera and Gilenya?
By answering these and other key strategic questions, Spherix aims to support our clients in making well-informed business decisions … to fuel winning strategies.
Direct from our Research!
The expanding use of orals into first-line position is putting pressure on nearly all of the platform injectables, but most notably on Teva’s Copaxone, for which surveyed neurologists have reported consecutive quarterly declines throughout 2016.
Despite approval delay, neurologists are very familiar with the Ocrevus (ocrelizumab) and many intend to use it as soon as it is approved. Although the greatest excitement for the drug is around the PPMS indication, many neurologists see a role for it in the larger RRMS population as well.